DUBLIN, Ireland, April 07, 2017 -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that it has been selected to the Crain’s Chicago Business 2017 “Best Places To Work” list.
“Horizon is a fast-growing company that takes great pride in building and maintaining a diverse and collaborative culture,” said Timothy P. Walbert, chairman, president and chief executive officer. “We know that our employee base is our greatest asset. This honor reinforces our commitment to making Horizon a great place to work which we do, in part, by attracting the best and brightest talent in the industry.”
The Crain's Chicago Business 2017 “Best Places To Work" designation is based on surveys conducted by Conduent, a global human resources organization. The firm surveyed Chicago-area businesses and employees about company benefits, pay, hiring practices, relationships with management and career development. This year, more than 14,900 Chicago-area employees participated. The complete report can be found at www.chicagobusiness.com.
About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.
Contacts: Geoff Curtis Senior Vice President, Corporate Communications [email protected]


TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Washington Post Publisher Will Lewis Steps Down After Layoffs
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Anta Sports Expands Global Footprint With Strategic Puma Stake
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



